New experiments suggest a biological missing link that helps lock in the long-term benefits of psychedelic-assisted PTSD treatment ...
"AtaiBeckley’s MDMA-based drug for anxiety shows benefit in Phase IIa trial" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.
Analysts consider AtaiBeckley’s MDMA candidate a “high-risk, high-reward” bet after the drug demonstrated reductions in ...
EMP-01 met its primary objective on safety and tolerability, demonstrating a generally favorable and manageable safety and tolerability ...
atai Life Sciences announces Phase 2 study of EMP-01 for social anxiety disorder, with results expected in Q1 2026. atai Life Sciences has announced the dosing of the first patient in a Phase 2 study ...
Also known as molly or ecstasy, MDMA has the potential to treat post-traumatic stress disorder (PTSD). But psychedelic-assisted therapy can only be administered by a trained professional. Without the ...
Sometimes tragedy yields important information. A recent peer-reviewed study published in the Journal of Psychopharmacology examined the psychological impact of psychoactive substance use among the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results